DUPIXENT demonstrated efficacy and safety across clinical trials
See how DUPIXENT reduced severe exacerbations, improved lung function, reduced or eliminated OCS use, and has demonstrated safety profile.
Adults and Pediatric Patients (12+ Years)
a With DUPIXENT 300 mg + SOC (n=64) vs placebo + SOC (n=68) in annualized rate of severe exacerbations through Week 24 in patients with baseline blood eosinophils ≥300 cells/μL (DRI12544, secondary endpoint).1
b 470 mL improvement at Week 52 from baseline in pre-bronchodilator FEV1 with DUPIXENT 200 mg + SOC (n=264) vs 170 mL improvement with placebo + SOC (n=148) (QUEST, EOS ≥300 cells/µL, secondary endpoint). ~72% of the total FEV1 improvement seen after the first dose at Week 2.1
c 75% of patients improved ACQ-5 (asthma control) score with DUPIXENT 200 mg + SOC vs 67% with placebo + SOC (OR: 1.46 [95% CI: 0.90, 2.35]) (QUEST, secondary endpoint).1
d 71% of patients improved AQLQ (quality of life) score with DUPIXENT 200 mg + SOC vs 55% with placebo + SOC (OR: 2.02 [95% CI: 1.24, 3.32]) (QUEST, secondary endpoint).1
Pediatric Patients (6-11 Years)
Demonstrated data across
Demonstrated safety profile
in pediatric patients (6-11
years) with asthma1
Studied up to 1 year in over
400 pediatric patients (6-11
years) with moderate-to-severe
ACQ-5. Asthma Control Questionnaire, 5-item version; AQLQ, Asthma Quality of Life Questionnaire; OR, odds ratio.